Screening for impulse control disorders in Parkinson's disease and dopamine agonist use: a study of pharmacokinetic and psychological risk factors.
Dopamine agonists
Impulse control disorders
Parkinson’s disease
Personality styles
Pharmacokinetics
QUIP
Journal
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
ISSN: 1590-3478
Titre abrégé: Neurol Sci
Pays: Italy
ID NLM: 100959175
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
23
09
2022
accepted:
28
10
2022
pubmed:
10
11
2022
medline:
19
1
2023
entrez:
9
11
2022
Statut:
ppublish
Résumé
Dopamine agonist (DA) use is considered the main risk factor for impulse control disorder (ICD) development in Parkinson's disease (PD). Besides DAs, personality traits and cognitive features may represent risk factors for ICDs. The primary aim of this study was to investigate differences in DA plasma concentrations in PD patients with and without a positive screening for ICDs according to validated tools. The secondary aim was to compare the psychological profile between ICD positive and negative screened patients. PD patients receiving chronic DA therapy were screened for ICDs according to the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease (QUIP). Blood samples for measurement of DA (pramipexole, ropinirole, rotigotine) trough plasma concentrations were drawn in the morning, at mean 16-19 h from the last DA dose. Patients' psychological profile was investigated by Millon Clinical Multiaxal Inventory III and Barratt Impulsiveness Scale (BIS-11). One hundred and five PD patients were enrolled. Forty-one patients (39%) were QUIP positive, mainly for binge eating and hobbyism. Median plasma concentrations of pramipexole (n = 71, 66%), ropinirole (n = 21, 19%), and rotigotine (n = 16, 15%) were similar between QUIP positive and negative patients. QUIP positive patients showed higher motor impulsiveness (p = 0.04) and tended to higher total impulsiveness (p = 0.05). This is the first prospective study to evaluate the relationship between DA plasma concentrations and ICDs risk in PD patients. DA plasma levels were overlapping between QUIP positive and negative patients. BIS-11, particularly the motor impulsiveness subscale, might be a useful screening tool in PD patients eligible for DA therapy.
Identifiants
pubmed: 36350455
doi: 10.1007/s10072-022-06485-y
pii: 10.1007/s10072-022-06485-y
doi:
Substances chimiques
Dopamine Agonists
0
rotigotine
87T4T8BO2E
Pramipexole
83619PEU5T
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
565-572Subventions
Organisme : Fondazione del Monte di Bologna e Ravenna
ID : 760bis/2019
Informations de copyright
© 2022. Fondazione Società Italiana di Neurologia.
Références
Tysnes OB, Storstein A (2017) Epidemiology of Parkinson’s disease. J Neural Transm (Vienna) 124:901–905. https://doi.org/10.1007/s00702-01(2017)7-1686-y
doi: 10.1007/s00702-01(2017)7-1686-y
Blandini F, Armentero MT (2014) Dopamine receptor agonists for Parkinson’s disease. Expert Opin Investig Drugs 23:387–410. https://doi.org/10.1517/13543784.2014.869209
doi: 10.1517/13543784.2014.869209
American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders (4th ed., Text Revision), Washington, DC. https://doi.org/10.1176/appi.books.9780890423349 .
Weintraub D, David AS, Evans AH, Grant JE, Stacy M (2015) Clinical spectrum of impulse control disorders in Parkinson’s disease. Mov Disord 30:121–127. https://doi.org/10.1002/mds.26016
doi: 10.1002/mds.26016
Kelly MJ, Baig F, Hu MT, Okai D (2020) Spectrum of impulse control behaviours in Parkinson’s disease: pathophysiology and management. J Neurol Neurosurg Psychiatry 91:703–711. https://doi.org/10.1136/jnnp-2019-322453
doi: 10.1136/jnnp-2019-322453
Rektorova I (2019) Current treatment of behavioral and cognitive symptoms of Parkinson’s Disease. Parkinsonism Relat Disord 59:65–73. https://doi.org/10.1016/j.parkreldis.2019.02.04
doi: 10.1016/j.parkreldis.2019.02.04
Probst CC, van Eimeren T (2013) The functional anatomy of impulse control disorders. Curr Neurol Neurosci Rep 13:386. https://doi.org/10.1007/s11910-013-0386-8
doi: 10.1007/s11910-013-0386-8
Seeman P (2015) Parkinson’s disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse 69:183–189. https://doi.org/10.1002/syn.21805
doi: 10.1002/syn.21805
Contin M, Lopane G, Mohamed S, Calandra-Buonaura G, Capellari S, De Massis P, Nassetti S, Perrone A, Riva R, Sambati L, Scaglione C, Cortelli P (2019) Clinical pharmacokinetics of pramipexole, ropinirole and rotigotine in patients with Parkinson’s disease. Parkinsonism Relat Disord 61:111–117. https://doi.org/10.1016/j.parkreldis.2018.11.007
doi: 10.1016/j.parkreldis.2018.11.007
Gatto EM, Aldinio V (2019) Impulse control disorders in Parkinson’s disease. A brief and comprehensive review. Front Neurol 10:351. https://doi.org/10.3389/fneur.2019.00351
doi: 10.3389/fneur.2019.00351
Weintraub D, Hoops S, Shea JA, Lyons KE, Pahwa R, Driver-Dunckley ED, Adler CH, Potenza MN, Miyasaki J, Siderowf AD, Duda JE, Hurtig HI, Colcher A, Horn SS, Stern MB, Voon V (2009) Validation of the questionnaire for impulsive compulsive disorders in Parkinson’s disease. Mov Disord 30:1461–1467. https://doi.org/10.1002/mds.22571
doi: 10.1002/mds.22571
Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30:1591–1601. https://doi.org/10.1002/mds.26424
doi: 10.1002/mds.26424
Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427–442. https://doi.org/10.1212/wnl.17.5.427
doi: 10.1212/wnl.17.5.427
Goetz CG, Stebbins GT, Chmura TA, Fahn S, Poewe W, Tanner CM (2010) Teaching program for the Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale: (MDS-UPDRS). Mov Disord 25:1190–1194. https://doi.org/10.1002/mds.23096
doi: 10.1002/mds.23096
Papay K, Mamikonyan E, Siderowf AD, Duda JE, Lyons KE, Pahwa R, Driver-Dunckley ED, Adler CH, Weintraub D (2011) Patient versus informant reporting of ICD symptoms in Parkinson’s disease using the QUIP: Validity and variability. Parkinsonism Relat Disord 17:153–155. https://doi.org/10.1016/j.parkreldis.2010.11.015
doi: 10.1016/j.parkreldis.2010.11.015
Zennaro A, Ferracuti S, Lang M, Sanavio E (2008) MCMI-III - Millon Clinical Multiaxial Inventory-III. Manuale. Adattamento italiano, Giunti OS FI Organizzazioni Speciali.
Patton JH, Stanford MS, Barratt E (1995) Factor structure of the Barratt Impulsiveness Scale. J Clin Psychol 51:768–774. https://doi.org/10.1002/1097-4679(199511)51:6%3c768::aid-jclp2270510607%3e3.0.co;2-1
doi: 10.1002/1097-4679(199511)51:6<768::aid-jclp2270510607>3.0.co;2-1
Measso G, Cavarzeran F, Zappalà G, Lebowitz BD, Crook TH, Pirozzolo FJ, Amaducci LA, Massari D, Grigoletto F (1993) The mini-mental state examination: Normative study of an Italian random sample. Dev Neuropsychol 77:77–85. https://doi.org/10.1080/87565649109540545
doi: 10.1080/87565649109540545
Appollonio I, Leone M, Isella V, Piamarta F, Consoli T, Villa ML, Forapani E, Russo A, Nichelli P (2005) The Frontal Assessment Battery (FAB): normative values in an Italian population sample. Neurol Sci 26:108–116. https://doi.org/10.1007/s10072-005-0443-4
doi: 10.1007/s10072-005-0443-4
Schade S, Mollenhauer B, Trenkwalder C (2020) Levodopa equivalent dose conversion factors: an updated proposal including opicapone and safinamide. Mov Disord Clin Pract 7:343–345. https://doi.org/10.1002/mdc3.12921
doi: 10.1002/mdc3.12921
Rizos A, Sauerbier A, Antonini A, Weintraub D, Martinez-Martin P, Kessel B, Henriksen T, Falup-Pecurariu C, Silverdale M, Durner G, Røkenes Karlsen K, Grilo M, Odin P, Chaudhuri KR (2016) A European multicentre survey of impulse control behaviours in Parkinson’s disease patients treated with short- and long-acting dopamine agonists. Eur J Neurol 23:1255–1261. https://doi.org/10.1111/ene.13034
doi: 10.1111/ene.13034
Joutsa J, Martikainen K, Vahlberg T, Kaasinen V (2012) Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson’s disease. Parkinsonism Relat Disord 18:1079–1083. https://doi.org/10.1016/j.parkreldis.2012.06.005
doi: 10.1016/j.parkreldis.2012.06.005
Lo Monaco MR, Petracca M, Weintraub D, Fusco D, Liperoti R, Zuccalà G, La Carpia D, Vetrano DL, Genovese D, Pisciotta MS, Brandi V, Padua L, Imbimbo I, Ricciardi D, Bernabei R, Silveri MC, Laudisio A, Bentivoglio AR (2018) Prevalence of impulsive-compulsive symptoms in elderly Parkinson’s Disease patients: a case-control study. J Clin Psychiatry 79:17m11612. https://doi.org/10.4088/JCP.17m11612
doi: 10.4088/JCP.17m11612
Evans AH, Okai D, Weintraub D, Lim SY, O’Sullivan SS, Voon V, Krack P, Sampaio C, Post B, Leentjens AFG, Martinez-Martin P, Stebbins GT, Goetz CG, Schrag A, Members of the International Parkinson and Movement Disorder Society (IPMDS) Rating Scales Review Committee (2019) Scales to assess impulsive and compulsive behaviors in Parkinson’s disease: critique and recommendations. Mov Disord 34:791–798. https://doi.org/10.1002/mds.27689
doi: 10.1002/mds.27689
Choca JP, Van Denburg EJ (1997) Interpretative Guide to the Millon Clinical Multiaxal Inventor, 2nd edn. American Psychological Association
Grall-Bronnec M, Victorri-Vigneau C, Donnio Y, Leboucher J, Rousselet M, Thiabaud E, Zreika N, Derkinderen P, Challet-Bouju G (2018) Dopamine agonists and impulse control disorders: a complex association. Drug Saf 41:19–75. https://doi.org/10.1007/s40264-017-0590-6
doi: 10.1007/s40264-017-0590-6
Canesi M, Lavolpe S, Cereda V, Ranghetti A, Maestri R, Pezzoli G, Rusconi ML (2020) Hypomania, depression, euthymia: new evidence in Parkinson’s Disease. Behav Neurol Article ID 5139237, 8. https://doi.org/10.1155/2020/5139237 .
Butcher JN, Dahlstrom WG, Graham JR, Tellegen A, Kaemmer B (1989) The Minnesota Multiphasic Personality Inventory-2 (MMPI-2) Manual for Administration and Scoring. University of Minnesota Press, Minneapolis, MN
Farnikova K, Obereigneru R, Kanovsky P, Prasko J (2012) Comparison of personality characteristics in Parkinson disease patients with and without impulse control disorders and in healthy volunteers. Cogn Behav Neurol 25:25–33. https://doi.org/10.1097/WNN.0b013e31824b4103
doi: 10.1097/WNN.0b013e31824b4103
Fossati A, Barratt ES, Borroni S, Villa D, Grazioli F, Maffei C (2007) Impulsivity, aggressiveness, and DSM-IV personality disorders. Psychiatry Res 149:157–167. https://doi.org/10.1016/j.psychres.2006.03.011
doi: 10.1016/j.psychres.2006.03.011
Santangelo G, Vitale C, Trojano L, Verde F, Grossi D, Barone P (2009) Cognitive dysfunction and pathological gambling in patients with Parkinson’s disease. Mov Disord 24:899–905. https://doi.org/10.1002/mds.22472
doi: 10.1002/mds.22472